Victoza
®
is the first and only human
GLP-1 analogue with 97 % homology
to natural GLP-1
1
Reduction in HbA
1C
2
Reduction in weight
1,3
Improvement in beta-cell function
3
Do more than lower blood glucose.
Grab diabetes
by the roots
™
For people with type 2 diabetes
Proprietary Name:
Victoza
®
.
Scheduling Status: S4 Composition:
Liraglutide 6 mg/ml.
Indications:
As an
adjunct to diet and exercise to achieve glycaemic control in patients with type 2 diabetes mellitus.
Registration Number:
43/21.13/0781. For full prescribing information refer to package insert approved
by the medicines regulatory authority.
Novo Nordisk (Pty) Ltd. Reg. No.: 1959/000833/07. 2nd Floor, Building A, 345 Rivonia Boulevard,
Edenburg, Rivonia, Sandton 2128, South Africa. Tel: (011) 202 0500 Fax: (011) 807 7989
VIC/ADVERT-MED/MAY/2013/1A
CINGULATE 9024
References: 1. Victoza
®
Package Insert. 2. Zinman B.,
et.al
. Achieving a clinically relevant composite outcome of an HbA
1c
of < 7 %
without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme.
Diabetes,
Obesity and Metabolism.
2012;14:77–82. 3. Pratley R.,
et.al
. One year of liraglutide treatment offers sustained and more effective
glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2
diabetes: a randomised, parallel-group, open-label trial.
Int J Clin Pract.
2011;65(4):397- 407. 4. Inzucchi S.E.,
et.al.
Management of
Hyperglycaemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA)
and the European Association for the Study of Diabetes (EASD)
Diabetes Care.
2012;35(6):1364-1379.
The ADA / EASD position statement includes use
of GLP-1 receptor agonists right after metformin
4
